Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 19, 2008

AstraZeneca Taps Cenix for RNAi Drug Discovery

  • Cenix BioScience will help AstraZeneca advance discovery activities and validate drug targets. Cenix will combine high-throughput (HT) applications of RNAi-based gene silencing with high-content phenotypic analyses in cultured human cells.

    The initial project will involve an HT-RNAi screen using an assay strategy codesigned with AstraZeneca to discover and validate oncology targets. Cenix will use Definiens’ Cellenger image-analysis platform to implement multiparametric microscopy-based assays. The company reports that this will lead to insights into cellular functions and loss-of-function phenotypes of analyzed genes.

    Cenix hopes to expand the collaboration beyond oncology into multiple projects, says Christophe Echeverri, CEO and CSO.

  • You’re all set! Thank you for subscribing to GEN Highlights.